ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith a copy of advertisement related to notice of loss of share certificates published by the Company on behalf of the shareholder(s) in English language newspaper - Business Standard on 7th May, 2019. We request you to kindly take the same on record. Alembic Pharmaceuticals Ltd - 533573 - Announcement under Regulation 30 (LODR)-Joint Venture
Pursuant to Regulation 30 of Listing Regulations, 2015, this is to inform the exchange that Alembic has entered into a Joint Venture Agreement ('JVA') dated 7th May, 2019 with SPH SINE Pharmaceutical Laboratories Co Ltd, China ('SPH Sine') & Adia (Shanghai) Pharma Co Ltd, China ('Adia'). Please find enclosed herewith our press release. The detailed disclosure pursuant to Regulation 30(2) of Listing Regulations, 2015 is enclosed herewith as Annexure - 1. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Alembic Pharmaceuticals Limited Announces Its Joint Venture, Aleor Dermaceuticals Ltd., Received Establishment Inspection Report (EIR) For Its Formulation Facility At Karkhadi
This is to inform the exchange that Aleor Dermaceuticals Ltd. (Aleor), a 60:40 Joint Venture between Alembic Pharmaceuticals Ltd (Alembic) and Orbicular Pharmaceutical Technologies Pvt. Ltd. (Orbicular), has received Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for the inspection carried out by them at Aleor's Formulation Facility at Karakhadi, Gujarat, India during the period from 4th February, 2019 to 8th February, 2019. We request you to kindly take the same on record. Alembic Pharmaceuticals Ltd - 533573 - Loss of Share Certificate / Issue of Duplicate Share Certificate
Alembic Pharmaceuticals Ltd has informed BSE regarding Loss of Share Certificate / Issue of Duplicate Share Certificate. Alembic Pharmaceuticals Ltd - 533573 - Alembic Pharmaceuticals receives USFDA Approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2%
Alembic Pharmaceuticals Ltd has informed BSE regarding a Press Release dated May 02, 2019, titled "Alembic Pharmaceuticals receives USFDA Approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2%". ALEMBIC PHARMACEUTICALS LTD. - 533573 - Compliances-Certificate under Reg. 54 (5) of SEBI (DP) Regulations, 1996
With reference to the captioned matter, please find enclosed herewith a Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 31st March, 2019, received from M/s. Link Intime India Private Limited, Registrar and Share Transfer Agent of our Company. We request you to kindly take the same on record. Alembic Pharmaceuticals Ltd - 533573 - Format of Initial Disclosure to be made by an entity identified as a Large Corporate
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompayALEMBIC PHARMACEUTICALS LTD. 2CININE901L01018 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 700 4Highest Credit Rating during the previous FY AA+Stable 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)CRISIL LTD. 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkNSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. YES Name of the Company Secretary: Charandeep Singh Saluja Designation: Company Secretary EmailId: charandeep.singh@alembic.co.in Name of the Chief Financial Officer: Rajkumar Shreeram Baheti Designation: Director - Finance & CFO EmailId: rajkumar_baheti@alembic.co.in Date: 24/04/2019 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. Alembic Pharmaceuticals Ltd - 533573 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith a copy of Notice of Board Meeting published in English and vernacular language (Gujarati) newspaper on 23rd April, 2019 in Economic Times English and Gujarati Edition. We request you to kindly take the same on record. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
The exchange is hereby informed that the Company will hold Post Results Conference Call on 8th May, 2019 as per the enclosed details. We request you to kindly take the same on record. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Board Meeting Intimation for Audited Financial Results For The Financial Year Ended On 31St March, 2019 And Recommend Dividend On Equity Shares, If Any, For The Financial Year Ended 31St March, 2019.
ALEMBIC PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/05/2019 ,inter alia, to consider and approve With reference to the captioned matter, the exchange is hereby informed that a Meeting of Board of Directors of the Company shall be held on 8th May, 2019, inter-alia to transact the following business: 1. To consider and approve Audited Financial Results of the Company for the financial year ended 31st March, 2019. 2. To consider and recommend dividend on Equity Shares, if any, for the financial year ended 31st March, 2019. We request you to kindly take the same on record.